Neurological Surgery 脳神経外科49巻3号

2021年05月発行

特集 グリオーマ—現在の常識と近未来のスタンダード Ⅱグリオーマの疫学と診断

—▼TOPICS—グリオーマの低侵襲的診断法—Liquid biopsyの現状および展望

著者： 棗田学¹ 温城太郎¹ 渡邉潤¹ 塚本佳広¹ 岡田正康¹ 藤井幸彦¹ 安達淳一² 西川亮²

所属機関： ¹新潟大学脳研究所脳神経外科 ²埼玉医科大学国際医療センター脳神経外科

ページ範囲：P.527 - P.534

Point
・脳腫瘍の低侵襲診断法liquid biopsyには，ddPCRによるctDNAの解析が有用である．
・ctDNAの検出精度を向上させるためには，脳脊髄液サンプル採取後に適正な処理が重要である．
・将来的には次世代シーケンスゲノムパネル検索や融合遺伝子解析が可能となると期待される．

参考文献

1）Louis DN, et al（eds）：WHO Classification of Tumours of the Central Nervous System（4th ed, revised ed）. International Agency for Research on Cancer Press, Lyon, 2016

2）Ignatiadis M, et al：Circulating tumor cells and circulating tumor DNA：challenges and opportunities on the path to clinical utility. Clin Cancer Res 21：4786-4800, 2015

3）Snyder MW, et al：Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164：57-68, 2016

4）Lo YMD, et al：Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64：218-224, 1999

5）Watanabe J, et al：Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leuk Lymphoma 60：3587-3589, 2019

6）Watanabe J, et al：High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas. JCO Precis Oncol 3, 2019　doi：10.1200/PO.18.00308

7）Fernando MR, et al：A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn 30：418-424, 2010

8）Kanemaru Y, et al：Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor：establishement and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun 7：119, 2019

9）Arita H, et al：Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126：267-276, 2013

10）Brat DJ, et al；Cancer Genome Atlas Research Network：Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372：2481-2498, 2015

11）Eckel-Passow JE, et al：Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372：2499-2508, 2015

12）Suzuki H, et al：Mutational landscape and clonal architecture in grade Ⅱ and grade Ⅲ gliomas. Nat Genet 47：458-468, 2015

13）Castel D, et al：Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130：815-827, 2015

14）Huang TY, et al：Detection of histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun 5：28, 2017

15）Pan C, et al：Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathol 137：297-306, 2019

16）Panditharatana E, et al：Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. Clin Cancer Res 24：5850-5859, 2018

17）Miller AM, et al：Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565（7741）：654-658, 2019

18）Piccioni DE, et al：Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol 8：CNS34, 2019

19）Parker M, et al：C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506（7489）：451-455, 2014

20）Jones DTW, et al：Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68：8673-8677, 2008

21）Wu G, et al：The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genet 46：444-450, 2014